Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-858 plus Gleevec in CML
NCT00058747Phase 2Terminated
- Sponsor
- Agenus Inc.
- Start
- Mar 2003
- Primary completion
- Apr 2006
- Modality
- Therapeutic Vaccines
- Countries
- 2
01
Overview
Phase 2, open-label trial of AG-858 in chronic myeloid leukemia (CML) (3 arms), sponsored by Agenus Inc. Primary endpoints: Complete Cytogenetic Response and Substantial Molecular Response. Started Mar 2003; status: terminated.
02
Drugs
AG-858
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00058747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00058747.